Familial colorectal cancer screening: When and what to do?

World J Gastroenterol. 2015 Jul 14;21(26):7944-53. doi: 10.3748/wjg.v21.i26.7944.

Abstract

Colorectal cancer (CRC) is the third leading cause of death worldwide and represents a clinical challenge. Family members of patients affected by CRC have an increased risk of CRC development. In these individuals, screening is strongly recommended and should be started earlier than in the population with average risk, in order to detect neoplastic precursors, such as adenoma, advanced adenoma, and nonpolypoid adenomatous lesions of the colon. Fecal occult blood test (FOBT) is a non invasive, widespread screening method that can reduce CRC-related mortality. Sigmoidoscopy, alone or in addition to FOBT, represents another screening strategy that reduces CRC mortality. Colonoscopy is the best choice for screening high-risk populations, as it allows simultaneous detection and removal of preneoplastic lesions. The choice of test depends on local health policy and varies among countries.

Keywords: Advanced adenoma; Colonoscopy; Colorectal cancer screening; Fecal occult blood test; First-degree relative; Sigmoidoscopy.

Publication types

  • Editorial
  • Review

MeSH terms

  • Biomarkers, Tumor / genetics
  • Colonoscopy*
  • Colorectal Neoplasms / blood
  • Colorectal Neoplasms / diagnosis*
  • Colorectal Neoplasms / genetics
  • Colorectal Neoplasms / pathology
  • Genetic Predisposition to Disease
  • Genetic Testing
  • Heredity
  • Humans
  • Mass Screening / methods*
  • Occult Blood*
  • Pedigree
  • Phenotype
  • Predictive Value of Tests
  • Prognosis
  • Risk Factors
  • Sigmoidoscopy

Substances

  • Biomarkers, Tumor